跳至主要内容
临床试验/NCT01858129
NCT01858129Unknown2 期

Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn in Infants Born at >34 Weeks Gestation: A Prospective, Randomized, Double Blind, Placebo Controlled Study.

Bnai Zion Medical Center1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
56
试验地点
1
主要终点
Assessment of respiratory distress

研究概览

简要总结

Transient Tachypnea of the Newborn (TTN) is a common respiratory disorder affecting late preterm and term babies caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid.

The investigators hypothesize that ENAC expression will be up-regulated as a result of administration of corticosteroids. This effect will lead to enhanced absorption of fetal lung fluid finally treating TTN. The aim of our study will be to evaluate whether inhaled corticosteroids reduce respiratory distress and morbidity in late preterm and term neonates presenting with TTN.

详细描述

The primary outcome measure will be the assessment of respiratory distress reflected by TTN clinical score in neonates presenting with TTN and treated with inhaled corticosteroids compared to placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
4 Hours 至 6 Hours(Child)
性别
All
接受健康志愿者

入选标准

  • Late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by cesarean section or vaginal delivery
  • Diagnosis of TTN
  • Parents signed informed consent

排除标准

  • Meconium aspiration syndrome
  • Respiratory distress syndrome
  • Congenital heart disease
  • Non respiratory disorders causing tachypnea

研究组 & 干预措施

Control

Placebo Comparator

Inhaled NS 0.9%

干预措施: placebo (Drug)

结局指标

主要结局

Assessment of respiratory distress

时间窗: 48 hours

The primary outcome measure will be the assessment of respiratory distress reflected by TTN clinical score in neonates presenting with TTN and treated with inhaled corticosteroids compared to placebo at 12, 24 and 48 hours after the first dose of inhaled study medication.

次要结局

  • The secondary outcome will be the assessment of morbidity associated with TTN(An average time period expected to be 5 days, according to the duration of hospital stay)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Kugelman Amir

Head, Pediatric Pulmonary Unit

Bnai Zion Medical Center

研究点 (1)

Loading locations...

相似试验